Tag: biotechnology
-
ALS Drug Maker Gains $135M in New Funds
A developer of treatments for people with amyotrophic lateral sclerosis, or ALS, is raising $135 million in its third venture financing round.
-
Trial to Test Antibody Drug for Alzheimer’s Prevention
Eli Lilly and Company is partnering with an Alzheimer’s disease research center to test a synthetic antibody for preventing the disorder in at-risk individuals.
-
Immune Cell Cancer Biotech Gains $172M in New Funds
A biotechnology company developing cancer therapies with natural killer cells in the immune system is raising $172 million in its second venture round.
-
$60M Challenge Seeks RNA Bio-Production Network
A new challenge competition aims to build a distributed network of facilities to design, develop, and manufacture RNA-based biologic products.
-
Precision Gene-Editing Biotech Gains $200M in New Funds
A biotechnology company says it discovers therapies with the gene-editing technique Crispr to carry out a wider range of precise genomic corrections.
-
Trial Underway for Crispr Lymphoma Therapy
A clinical trial enrolled its first participant testing the safety of a treatment for lymphoma, a type of cancer, using the gene-editing technique Crispr.
-
Neuro Disease Start-Up Raises $73M in Early Funds
A new enterprise discovering treatments for neurodegenerative diseases is merging with another start-up and raising $73 million its first venture round.
-
Infographic – Biotech Index Rebounds in Q2
Since mid-May, NBI rose steadily, closing at 5,148 by the end of June, a gain of nine percent for the quarter and eight percent for the year.
-
GSK, Biotech Partner on Neuro Antibodies in $2.2B Deal
GlaxoSmithKline and biotechnology company Alector Inc. agreed to co-develop two synthetic antibodies for treating neurodegenerative disorders.
-
Microbiome Drug Candidate Licensed in $525M Deal
A therapy designed to regenerate healthy gut microbes for treating dangerous intestinal infections is licensed for commercialization to Nestlé Health Science.